SCHEMBL256764

SCHEMBL256764

CCOC(=O)c1c(C)cc(C(=O)c2ccccc2)n1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
MAPT P10636 4/20 0.49
GAA P10253 3/20 0.49
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 8/20 0.44
NPC1 O15118 5/20 0.44
RAB9A P51151 4/20 0.44
KDM4E B2RXH2 5/20 0.44
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
PTGS2 P35354 1/20 0.44
HPGD P15428 3/20 0.44
TSHR P16473 2/20 0.44
SIRT3 Q9NTG7 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257496 0.84 ALDH1A1 (0.48) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL15100671 0.84 ALDH1A1 (0.45) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL10046853 0.83 FNTA (0.44) ALDH1A1MAPTSMN1; SMN2PTGS2HPGD
SCHEMBL11195139 0.83 KMT2A (0.49) ALDH1A1MAPTGAAKMT2ASMN1; SMN2
SCHEMBL15197093 0.82 MAPT (0.42) ALDH1A1MAPTKMT2ASMN1; SMN2PTGS2
SCHEMBL11064170 0.78 HTT (0.46) ALDH1A1MAPTGAAKMT2ASMN1; SMN2
SCHEMBL257221 0.75 KMT2A (0.69) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL7680326 0.75 MEN1 (0.44) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL11355497 0.75 KMT2A (0.50) ALDH1A1MAPTGAAKMT2ASMN1; SMN2
SCHEMBL16110173 0.74 KDM4E (0.58) ALDH1A1GAAMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 ALDH1A1 538/4885MAPT 3973/4885GAA 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.